Diluting a Cannabinoid Urine Sample Did Not Preserve Every Analyte Equally
A dilution factor is not automatically a valid correction for every compound in a cannabinoid panel. During validation of a urine LC–MS/MS assay, a greater dilution preserved acceptable results for some metabolites while causing unacceptable losses for several other targets.
Why laboratories validate dilution separately
The method directly measured THC, 11-hydroxy-THC, THC-COOH, CBD, CBN and two cannabinoid glucuronides in human urine. Dilution experiments used fortified urine with known target concentrations.
Adding blank urine can bring a concentrated specimen into a calibration range. Multiplying the measured value by the dilution factor is justified only if the preparation continues to produce sufficiently accurate results for that analyte.
The acceptable dilution depended on the target
A 1:1 dilution with blank urine met the study’s acceptance criterion for all seven analytes. In the larger dilution experiment, described in the results as one part sample to three parts blank urine, THC-COOH and the two glucuronides remained within the specified limits.
THC, 11-hydroxy-THC, CBD and CBN did not. Their measured concentrations fell below the expected diluted values by more than the accepted approximately 20% margin. An acceptable metabolite result therefore could not validate the parent compound by association.
The cause remained uncertain
The authors considered adsorption to tubes or precipitated material as possible explanations for losses. They did not establish the mechanism. Because some analytes passed while others failed, a single pipetting error was not their preferred explanation.
The paper’s methods and results use different dilution notation for the larger experiment. Interpretation should follow the stated preparation and analyte-specific findings, rather than relying on an ambiguous shorthand alone.
Limits on applying these results
These were fortified-specimen validation experiments, not evidence that every diluted urine sample or every laboratory method loses the same amount. The clinical proof of method involved urine from one smoker and did not establish population-wide dilution behavior.
For a particular laboratory report, request the actual dilution procedure, validated factor, analyte-specific acceptance data and repeat-analysis policy. Dilution integrity addresses concentration measurement; it does not establish dose, time of last use or impairment. A cannabinoid panel should be reviewed as several measured compounds, each with its own analytical limits.
Related: Interpreting THC concentration and impairment.
Primary research
Simultaneous Quantification of Free and Glucuronidated Cannabinoids in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry. DOI: 10.1016/j.cca.2012.06.034.
